Indian Court Nixes Roche's Bid To Bar Generic Tarceva

Law360, New York (March 19, 2008, 12:00 AM EDT) -- Cipla received a boost on Wednesday when the High Court of Delhi reportedly refused to intercept the Indian generics maker's efforts to manufacture and market F. Hoffmann-La Roche Ltd.'s cancer drug Tarceva without a compulsory license.

The court issued an interim order declining Roche's application to stay further sales of Cipla's copycat drug, Reuters reported Wednesday, citing a Cipla official.

Amar Lulla, a joint managing director at Cipla, said the company was selling generic erlotinib at one-third of the price charged by the Swiss firm, Reuters...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.